To investigate whether the endogenous neuropeptide nociceptin/orphanin FQ (N/OFQ) contributes to the death of dopamine neurons in Parkinson's disease, we undertook a genetic and a pharmacological approach using NOP receptor knockout (NOP −/− ) mice, and the selective and potent small molecule NOP receptor
To investigate whether the endogenous neuropeptide nociceptin/orphanin FQ (N/OFQ) contributes to the death of dopamine neurons in Parkinson's disease, we undertook a genetic and a pharmacological approach using NOP receptor knockout (NOP −/− ) mice, and the selective and potent small molecule NOP receptor ,7,8,9-tetrahydro-5H-benzocyclohepten-5-ol (SB-612111) . Stereological unbiased methods were used to estimate the total number of dopamine neurons in the substantia nigra of i) NOP −/− mice acutely treated with the parkinsonian neurotoxin 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP), ii) naïve mice subacutely treated with MPTP, alone or in combination with SB-612111, iii) rats injected with a recombinant adeno-associated viral (AAV) vector overexpressing human mutant p.A53T α-synuclein, treated with vehicle or SB-612111. NOP −/− mice showed a 50% greater amount of nigral dopamine neurons spared in response to acute MPTP compared to controls, which was associated with a milder motor impairment. SB-612111, given 4 days after MPTP treatment to mimic the clinical condition, prevented the loss of nigral dopamine neurons and striatal dopaminergic terminals caused by subacute MPTP. SB-612111, administered a week after the AAV injections in a clinically-driven protocol, also increased by 50% both the number of spared nigral dopamine neurons and striatal dopamine terminals, and prevented accompanying motor deficits induced by α-synuclein. We conclude that endogenous N/OFQ contributes to dopamine neuron loss in pathogenic and etiologic models of Parkinson's disease through NOP receptor-mediated mechanisms. NOP receptor antagonists might prove effective as disease-modifying agents in Parkinson's disease, through the rescue of degenerating nigral dopamine neurons and/or the protection of the healthy ones. © 2016 Elsevier Inc. All rights reserved. 
Introduction
Nociceptin/orphanin FQ is an opioid-like neuropeptide that selectively activates the N/OFQ peptide (NOP) receptor (Meunier et al., 1995; Reinscheid et al., 1995) . N/OFQ and its receptor are expressed in cortical and subcortical areas of the central nervous system (Neal et al., 2001; Neal et al., 1999a; Neal et al., 1999b) , and contribute to the modulation of a number of central functions such as pain, reward, food intake, mood and locomotion (Calo et al., 2000; Lambert, 2008; Mogil and Pasternak, 2001) . Mesencephalic dopamine (DA) neurons are involved in motor effects of N/OFQ (Florin et al., 1996; Kuzmin et al., 2004; Viaro et al., 2013) . In fact, DA neurons projecting from substantia nigra compacta (SNc) and ventral-tegmental area to the striatum and prefrontal cortex express the NOP receptor (Maidment et al., 2002; Norton et al., 2002) . Activation of somato-dendritic NOP receptors causes inhibition of the firing activity along the nigro-striatal (Marti et al., 2004b) and meso-accumbal (Murphy and Maidment, 1999) pathways, while activation of presynaptic NOP receptors causes inhibition of DA neurosecretion (Flau et al., 2002) . These effects have been associated with hypolocomotion (Murphy, 2010; Narayanan 
